Formally protected. Independently verifiable. Published by WIPO
The formulations and peptides derived from Heteroctenus junceus blue scorpion venom are now protected under international intellectual property law — filed under the Patent Cooperation Treaty and published by the World Intellectual Property Organization in November 2025.
What a PCT patent
application means
A PCT (Patent Cooperation Treaty) application is an international patent filing that simultaneously seeks protection in over 150 countries through a single procedure administered by the World Intellectual Property Organization (WIPO).
Publication by WIPO means the invention has been formally registered, assigned an international publication number, and made publicly accessible in the global patent database — Patentscope.
These two applications represent the formal intellectual property protection of 18 years of scientific research on blue scorpion venom compounds.
These are international patent applications currently in the evaluation phase. They have been published by WIPO but have not yet been granted. Patent applications do not imply FDA approval. NDC registration is separate from patent status.
Patents
Pharmaceutical compositions based on fractions of Heteroctenus junceus blue scorpion venom
November 27, 2025
- International Application: PCT/CL2025/050057
- Filing Date: May 23, 2025
- Priority Data: CL 202401571 — May 24, 2024
- IPC Classification: A61K 35/646 · A61K 38/17 · C07K 4/12 · C07K 14/435 · A61P 35/00
- Inventors: Diaz Garcia, Alexis · Portal Artiles, Ariel · Hernandez Munoz, Darlenys · Varela Lekanda, Diego Ernst · Meneses Sepulveda, Lorena Angelica · Garrido Medina, Angel Jesus
- Official Link: patentscope.wipo.int/search/es/detail.jsf?docId=WO2025241039
This application describes pharmaceutical compositions based on fractions F4 and F5.3 of Heteroctenus junceus venom, individually or in combination. The described compositions present potential anticancer activity associated with the inhibition of tumor progression, alongside reduced cardiac toxicity and high antimicrobial stability.
Peptides derived from Heteroctenus junceus blue scorpion venom — variants, compositions, methods and pharmaceutical uses
November 27, 2025
- International Application: PCT/CL2025/050058
- Filing Date: May 23, 2025
- Priority Data: CL 202401571 — May 24, 2024
- IPC Classification: A61K 35/646 · A61K 38/17 · C07K 4/12 · C07K 14/435 · A61P 35/00
- Inventors: Diaz Garcia, Alexis · Portal Artiles, Ariel · Hernandez Munoz, Darlenys · Varela Lekanda, Diego Ernst · Meneses Sepulveda, Lorena Angelica · Garrido Medina, Angel Jesus · Ruiz Fuentes, Jenny Laura
- Official Link: patentscope.wipo.int/search/es/detail.jsf?docId=WO2025241040
This application covers specific peptides derived from Heteroctenus junceus venom, including their structural variants, pharmaceutical compositions containing them, methods of production and purification, and potential uses — particularly in experimental models related to tumor progression and metastasis-associated processes.
Escozul® is registered in the United States under the FDA's National Drug Code (NDC) directory — the federal system used to identify and track drug and wellness products in U.S. commercial distribution.
NDC Number: 87019-001-01
NDC registration identifies a product within the FDA’s tracking system. It does not constitute FDA approval, certification, or endorsement of the product, its safety, or its efficacy. These statements have not been evaluated by the Food and Drug Administration.